Indantadol

Indantadol

Systematic (IUPAC) name
N-(2,3-dihydro-1H-inden-2-yl)glycinamide
Clinical data
Legal status	Uncontrolled
Routes of administration	Oral
Identifiers
CAS Number	202844-10-8
ATC code	none
ChemSpider	16017060
UNII	Z3867B9SQP Y
Chemical data
Formula	C11H14N2O
Molecular mass	190.24 g/mol
SMILES NCC(=O)NC1Cc2ccccc2C1

Indantadol (CHF-3381, V-3381) is a drug which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.

See also

• 2-Aminoindane
• Glycine